The ChronVac-C DNA vaccine delivered by in vivo electroporation using the Medpulser
was recently reported to be safe and generate antigen specific immune responses as well as antiviral effects in a Phase I/IIa clinical trial.
The application is designed to permit initial clinical testing of Tripep's proprietary DNA vaccine, ChronVac-C, administered using Inovio's MedPulser
DNA Delivery System.
The company is moving its lead product, the MedPulser
Based on the promising results from patients with chronic hepatitis C virus infection who after vaccination with ChronVac-C delivered by Inovios Medpulser DDS underwent standard-of-care treatment, ChronTech filed applications to start a Phase IIb clinical trial.
In the Phase IIb clinical study patients with genotype 1 chronic hepatitis C will be grouped to receive, or not to receive, two vaccinations with ChronVac-C delivered by Inovios Medpulser DDS immediately followed by standard-of-care treatment with ribavirin and interferon.
Inovio is moving its lead product, the MedPulser
, through pre-marketing studies for head and neck cancer and skin cancers in Europe, where it has CE Mark accreditation; a U.S.
Inovio Biomedical Corporation today announced that its partner, Tripep AB of Sweden, recently demonstrated that Tripep's proprietary DNA vaccine, ChronVac-C, administered using Inovio's MedPulser DNA Drug Delivery System, activated a T-cell response in mice that appears capable of clearing liver cells expressing hepatitis C virus protein in a murine model of hepatitis C.
The data was obtained in support of a planned application for a clinical trial designed to test the therapeutic use of the combination of the ChronVac-C DNA vaccine and Inovio's MedPulser gene delivery system in chronic hepatitis C infections.